FIGHT against FGF/FGFR alterations: what are the next steps?

Ann Oncol. 2022 May;33(5):460-462. doi: 10.1016/j.annonc.2022.03.014.

Authors

A Bayle¹, P Martin-Romano¹, Y Loriot²

Affiliations

¹ Drug Development Department (DITEP), Gustave Roussy - Université Paris-Saclay, Villejuif, France.
² Drug Development Department (DITEP), Gustave Roussy - Université Paris-Saclay, Villejuif, France. Electronic address: yohann.loriot@gustaveroussy.fr.

PMID: 35450697
DOI: 10.1016/j.annonc.2022.03.014

No abstract available

Publication types

Editorial
Comment

MeSH terms

Fibroblast Growth Factors* / genetics
Humans
Receptor, Fibroblast Growth Factor, Type 1
Receptor, Fibroblast Growth Factor, Type 2*

Substances

Fibroblast Growth Factors
Receptor, Fibroblast Growth Factor, Type 1
Receptor, Fibroblast Growth Factor, Type 2